Medtronic settles antitrust charges in Avecor acquisition
This article was originally published in Clinica
Medtronic has agreed to divest Avecor's non-occlusive arterial pump technology to settle US antitrust charges that its $106 million acquisition of the company would reduce competition.
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.